Kelly Mccabe Guthrie

US Patent:

6656906, Dec 2, 2003

Filed:

Jul 9, 1999

Appl. No.:

09/350641

Inventors:

Shawn Barney - Apex NC
Kelly I. Guthrie - Virginia Beach VA
Gene Merutka - Saratoga CA
Mohmed K. Anwer - Foster City CA
Dennis M. Lambert - Cary NC

Assignee:

Trimeris, Inc. - Durham NC

International Classification:

A61K 3816

US Classification:

514 12, 514 2, 514 13, 514 15, 530300, 530324, 530326, 530328, 530350

Abstract:

The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.

US Patent:

7297784, Nov 20, 2007

Filed:

Jan 24, 2003

Appl. No.:

10/351641

Inventors:

Shawn Barney - Apex NC, US
Kelly I. Guthrie - Virginia Beach VA, US
Gene Merutka - Saratoga CA, US
Mohmed K. Anwer - Foster City CA, US
Dennis M. Lambert - Cary NC, US

Assignee:

Trimeris, Inc. - Morrisville NC

International Classification:

C07H 21/04
A61K 39/21

US Classification:

536 2372, 4241881

Abstract:

The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.